Physician profile
Gary Michael Early
NPI 1215913132
$1,334.77
in general payments reported to CMS, 2019-2025
27 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $191 · 2021: $294 · 2022: $150 · 2023: $93.66 · 2024: $248 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $252.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $146.19 | 2019-2025 | Zoryve |
| Abbvie INC. | $133.77 | 2021-2024 | |
| Amgen INC. | $116.84 | 2023-2024 | Evenity, Prolia, Repatha |
| Supernus Pharmaceuticals, INC. | $66.50 | 2019-2022 | |
| Grifols USA, LLC | $62.25 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $55.20 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $40.83 | 2021-2022 | |
| Verona Pharma, INC. | $39.65 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $37.23 | 2025 | Yupelri |
| Amarin Pharma, INC. | $33.95 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $33.27 | 2024-2025 | Airsupra |
| Vertex Pharmaceuticals Incorporated | $32.00 | 2025 | |
| Exact Sciences Corporation | $31.94 | 2024-2025 | Cologuard Collection Kit |
| Ucb, INC. | $31.07 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $26.29 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $26.18 | 2022 | |
| Harmony Biosciences LLC | $25.05 | 2021 | |
| Sanofi Pasteur INC. | $23.70 | 2019 | |
| Eisai INC. | $23.20 | 2020 | |
| Almatica Pharma LLC | $21.13 | 2021 | |
| Radius Health, INC. | $16.34 | 2025 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $15.97 | 2022 | |
| Pfizer INC. | $15.22 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.59 | 2022 | |
| Abbott Laboratories | $11.74 | 2022 | |
| Sumitomo Pharma America, INC. | $4.33 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Early listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.